VRTX Vertex Pharmaceuticals Incorporated

HealthcareBiotechnology

$425.32

▼ 0.54%

QScore Signal

Hold

Confidence: MEDIUM

Long-Term

Short-Term

Value

P/E24.91

P/B5.58

P/S8.81

EV/EBITDA20.14

Growth

Revenue Growth9.6%

EPS Growth843.3%

100

FCF Growth504.1%

100

Momentum

12-Month Return-5.4%

3-Month Return-7.2%

1-Month Return-4.1%

RSI (14)35.29

50/200 MABullish

Profitability

ROE23.9%

ROA16.4%

Gross Margin86.3%

Operating Margin39.0%

Net Margin35.4%

FCF Yield3.4%

Risk

Beta0.30

60-Day Volatility32.0%

Generated 5/7/2026, 7:47:48 PM · How is this calculated?

QScore Analysis

The QScore of 54 for Vertex Pharmaceuticals indicates a neutral outlook, driven by strong growth prospects and solid profitability, with scores of 82 and 65, respectively. However, the stock's value score of 42 is a drawback, as it trades at a premium with a P/E of 24.9. The company exhibits strong momentum in its financials, with significant revenue and EPS growth, but its price momentum is weaker, with a -5.4% return over the past year and an RSI of 35.3. The long-term and short-term scores are relatively aligned, suggesting a consistent view of the company's prospects.

Generated by AI from the underlying QScore factors. Not investment advice.

QScore Analysis